» Articles » PMID: 33233550

OX-HDL: A Starring Role in Cardiorenal Syndrome and the Effects of Heme Oxygenase-1 Intervention

Overview
Specialty Radiology
Date 2020 Nov 25
PMID 33233550
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

In this review, we will evaluate how high-density lipoprotein (HDL) and the reverse cholesterol transport (RCT) pathway are critical for proper cardiovascular-renal physiology. We will begin by reviewing the basic concepts of HDL cholesterol synthesis and pathway regulation, followed by cardiorenal syndrome (CRS) pathophysiology. After explaining how the HDL and RCT pathways become dysfunctional through oxidative processes, we will elaborate on the potential role of HDL dysfunction in CRS. We will then present findings on how HDL function and the inducible antioxidant gene heme oxygenase-1 (HO-1) are interconnected and how induction of HO-1 is protective against HDL dysfunction and important for the proper functioning of the cardiovascular-renal system. This will substantiate the proposal of HO-1 as a novel therapeutic target to prevent HDL dysfunction and, consequently, cardiovascular disease, renal dysfunction, and the onset of CRS.

Citing Articles

Antioxidant and Anti-Inflammatory Effects of Bioactive Compounds in Atherosclerosis.

Rosian S, Boarescu I, Boarescu P Int J Mol Sci. 2025; 26(3).

PMID: 39941147 PMC: 11818840. DOI: 10.3390/ijms26031379.


Cardiorenal syndrome: clinical diagnosis, molecular mechanisms and therapeutic strategies.

Zhao B, Hu X, Wang W, Zhou Y Acta Pharmacol Sin. 2025; .

PMID: 39910210 DOI: 10.1038/s41401-025-01476-z.


GPR75: A Newly Identified Receptor for Targeted Intervention in the Treatment of Obesity and Metabolic Syndrome.

Fragner M, Parikh M, Jackson K, Schwartzman M, Frishman W, Peterson S Cardiol Rev. 2024; .

PMID: 38695569 PMC: 11808825. DOI: 10.1097/CRD.0000000000000711.


NAC Pre-Administration Prevents Cardiac Mitochondrial Bioenergetics, Dynamics, Biogenesis, and Redox Alteration in Folic Acid-AKI-Induced Cardio-Renal Syndrome Type 3.

Cuevas-Lopez B, Romero-Ramirez E, Garcia-Arroyo F, Tapia E, Leon-Contreras J, Silva-Palacios A Antioxidants (Basel). 2023; 12(8).

PMID: 37627587 PMC: 10451243. DOI: 10.3390/antiox12081592.


Cardio-Renal Metabolic Syndrome: Interdisciplinary Diagnostic Methods.

Bungau S Diagnostics (Basel). 2023; 13(2).

PMID: 36673075 PMC: 9858236. DOI: 10.3390/diagnostics13020265.


References
1.
Virzi G, Breglia A, Brocca A, De Cal M, Bolin C, Vescovo G . Levels of Proinflammatory Cytokines, Oxidative Stress, and Tissue Damage Markers in Patients with Acute Heart Failure with and without Cardiorenal Syndrome Type 1. Cardiorenal Med. 2018; 8(4):321-331. PMC: 6477492. DOI: 10.1159/000492602. View

2.
Virzi G, Clementi A, De Cal M, Brocca A, Day S, Pastori S . Oxidative stress: dual pathway induction in cardiorenal syndrome type 1 pathogenesis. Oxid Med Cell Longev. 2015; 2015:391790. PMC: 4364374. DOI: 10.1155/2015/391790. View

3.
Cao J, Sodhi K, Inoue K, Quilley J, Rezzani R, Rodella L . Lentiviral-human heme oxygenase targeting endothelium improved vascular function in angiotensin II animal model of hypertension. Hum Gene Ther. 2010; 22(3):271-82. PMC: 3057195. DOI: 10.1089/hum.2010.059. View

4.
Waldman M, Cohen K, Yadin D, Nudelman V, Gorfil D, Laniado-Schwartzman M . Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving 'SIRT1 and PGC-1α'. Cardiovasc Diabetol. 2018; 17(1):111. PMC: 6090985. DOI: 10.1186/s12933-018-0754-4. View

5.
Pussinen P, Jauhiainen M, Metso J, PYLE L, Marcel Y, FIDGE N . Binding of phospholipid transfer protein (PLTP) to apolipoproteins A-I and A-II: location of a PLTP binding domain in the amino terminal region of apoA-I. J Lipid Res. 1998; 39(1):152-61. View